Molecular therapeutics for anaplastic thyroid cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Anaplastic thyroid cancer (ATC) is a rare but highly lethal malignancy, responsible for most thyroid cancer deaths.
• Limited targeted therapies exist, with only one approved for BRAF-mutant ATC, highlighting the need for new therapeutic strategies.

Purpose of the Study:

• To summarize recent genomic findings in ATC.
• To explore the genetic landscape of ATC and identify novel therapeutic targets.
• To discuss emerging therapies targeting identified genetic alterations.

Main Methods:

• Review of recent next-generation sequencing studies on ATC genomics.
• Analysis of genetic alterations in key pathways including MAPK, PI3K, and DNA repair.
• Integration of findings on cell cycle, chromatin remodeling, and cytidine deaminase genes.

Main Results:

• Confirmed MAPK pathway mutations (BRAF, RAS) in differentiated thyroid cancer and identified additional alterations (PI3K, TP53, TERT promoter) crucial for anaplastic transformation.
• Discovered high mutational burden in ATC linked to Mismatch Repair (MMR) pathway mutations and AID/APOBEC overactivity.
• Identified novel mutations in cell cycle, SWI/SNF chromatin remodeling, histone modification genes, and RAC1, impacting BRAF-directed therapies.

Conclusions:

• The genetic landscape of ATC is complex, involving multiple pathways beyond BRAF.
• Novel mutations in MMR, AID/APOBEC, cell cycle, and chromatin remodeling genes present new therapeutic opportunities.
• Ongoing clinical and preclinical studies are evaluating targeted therapies for ATC based on these genomic discoveries.